Cellectis (CLLS) PT Lowered to $8 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CLLS Hot Sheet
Price: $0.98 +1.03%
Rating Summary:
10 Buy, 5 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Rating Summary:
10 Buy, 5 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Join SI Premium – FREE
Baird analyst Madhu Kumar lowered the price target on Cellectis (NASDAQ: CLLS) to $8.00 (from $10.00) while maintaining a Outperform rating.
You May Also Be Interested In
- argenx SE (ARGX) PT Raised to $861 at Baird
- Lazard (LAZ) PT Raised to $35 at Goldman Sachs
- Danaher (DHR) PT Raised to $260 at Stifel as Nonrespiratory Core Growth Exceeded Expectations
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
